ImmunityBio’s European Launch Sets Stage for Critical Financial Update

All eyes are on ImmunityBio today as the biotechnology firm prepares to release its full-year 2025 results. This follows the recent European approval of its key drug candidate, Anktiva, with investors keen to see if the company can translate its operational momentum into sustainable financial performance.

A Pivotal Financial Disclosure

The management team is scheduled to detail the complete business figures and provide forward guidance today at 1:30 PM Pacific Time. Market sentiment is already buoyant, fueled by reports from yesterday indicating a stronger-than-anticipated financial performance for the last quarter. The company’s loss was narrower than analysts had projected, while revenues from its cancer therapy, Anktiva, showed significant year-over-year growth for 2025. Today’s conference call will be scrutinized for confirmation that this positive trajectory is continuing.

Commercial Expansion Gains Momentum

The fundamental driver behind the current progress is the commercialization of Anktiva. The recent authorization for treating bladder cancer in Europe grants the company access to 33 new markets. To manage distribution efficiently, ImmunityBio has entered a collaboration with Accord Healthcare. This international push is further supported by regulatory advancements in other regions, including Saudi Arabia.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Clinical Pipeline Advances

Alongside its commercial efforts, the company continues to advance its clinical research. Patient recruitment has been completed for a crucial Phase 2 trial investigating Anktiva in combination with BCG for a specific subset of bladder cancer patients. Based on the data from this study, ImmunityBio intends to submit an additional marketing application to the U.S. Food and Drug Administration (FDA) by the fourth quarter of 2026.

Today’s update is expected to set the agenda for the coming months. Key focal points will be the specific revenue forecast for 2026 and the detailed timeline for the further international rollout of its therapies.